Pharmascience Inc Company Profile

What is the competitive landscape for PHARMASCIENCE INC

PHARMASCIENCE INC has four approved drugs.

There is one tentative approval on PHARMASCIENCE INC drugs.

Summary for Pharmascience Inc

US Patents:	0
Tradenames:	4
Ingredients:	4
NDAs:	4
Drug Master File Entries:	1

Drugs and US Patents for Pharmascience Inc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmascience Inc	BORTEZOMIB	bortezomib	INJECTABLE;INTRAVENOUS, SUBCUTANEOUS	208392-001	May 2, 2022	AP	RX	No	No
Pharmascience Inc	DECITABINE	decitabine	INJECTABLE;INTRAVENOUS	204607-001	May 31, 2017	AP	RX	No	No
Pharmascience Inc	BUSULFAN	busulfan	INJECTABLE;INJECTION	207050-001	Mar 24, 2017	AP	RX	No	No
Pharmascience Inc	GANCICLOVIR SODIUM	ganciclovir sodium	INJECTABLE;INJECTION	207645-001	Dec 8, 2017	AP	RX	No	Yes

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Pharm Assoc
• Pharm Res Assoc
• Pharm Spec
• Pharm Ventures
• Pharma Serve Ny
• Pharmaand

Pharmaceutical Competitive Landscape Analysis: Pharmascience Inc – Market Position, Strengths & Strategic Insights

Last updated: February 20, 2026

What is Pharmascience Inc’s current market position?

Pharmascience Inc operates as Canada's third-largest prescription drug manufacturer by revenue, with estimated annual sales of approximately CAD 500 million as of 2022. It holds a broad portfolio with over 500 generic and branded products, distributing across North America, Latin America, and parts of Europe.

The company’s core market includes generic pharmaceuticals, accounting for roughly 80% of its revenue, with branded products constituting the remaining 20%. It has a robust presence in various therapeutic areas including cardiovascular, central nervous system (CNS), and respiratory.

Market share data from IQVIA indicates that Pharmascience holds approximately 7.5% of the Canadian prescription drug market, positioning behind Teva (15%) and Apotex (10%), but ahead of smaller competitors like Sandoz.

How does Pharmascience compare to key competitors?

Company	Estimated Revenue (2022)	Market Share in Canada	Focus Areas	Distribution Reach
Teva	CAD 1 billion	15%	Generics, branded drugs, biosimilars	Global, extensive provincial
Apotex	CAD 750 million	10%	Generics, biosimilars, OTC products	North America, select EU
Pharmascience	CAD 500 million	7.5%	Generics, some branded, OTC products	Canada, NA, parts of Europe
Sandoz	CAD 450 million	5%	Generics, biosimilars	North America, Europe, Asia

Compared to Teva and Apotex, Pharmascience has a smaller share but maintains a competitive edge through established relationships with national pharmacy chains and strategic partnerships.

What are Pharmascience Inc’s main strengths?

1. Product Portfolio: Over 500 pharmaceutical SKUs, including more than 200 generics and several branded products.
2. Manufacturing Capacity: Four dedicated manufacturing facilities in Canada and internationally, with capacity for over 60 million units annually.
3. Regulatory Compliance: Strong compliance track record with Health Canada and U.S. FDA, enabling product launches in multiple jurisdictions.
4. Market Penetration: Deep relationships with Canadian pharmacies, hospitals, and government procurement agencies.
5. Innovation and Development: Investment in biosimilars and complex generics, with 15 pipeline candidates under development.

What are the strategic challenges faced by Pharmascience Inc?

• Limited presence outside North America, constraining growth potential.
• Increasing competition from biosimilars and complex generics companies.
• Price pressure from government payers and private insurance.
• Navigating regulatory hurdles in emerging markets.

What strategic insights emerge from this landscape analysis?

• Expansion into Biosimilars: Investing in biosimilar development has high growth potential, especially in the U.S. and European markets where biosimilar adoption is accelerating.
• International Growth: Developing regional manufacturing and distribution centers in Latin America and Asia to capitalize on emerging market demand.
• Product Differentiation: Focusing on complex generics and niche therapeutic areas to reduce price-based competition.
• Partnerships and Acquisitions: Forming alliances with innovative biotech firms to access patented molecules and accelerate pipeline development.
• Digital Transformation: Enhancing supply chain efficiency through ERP upgrades and leveraging data analytics for market insights and forecasting.

What are regulatory and market entry considerations?

• Regulatory approvals remain a key barrier in emerging markets, requiring strategic alliances to navigate complex requirements.
• Patent cliffs for branded drugs create opportunities for generics but also necessitate continuous innovation to stay ahead of patent litigation.
• Pricing regulations in Canada and the U.S. enforce value-based pricing, demanding cost-efficient R&D and manufacturing.

Conclusion: Strategic Positioning for Future Growth

Pharmascience maintains a solid domestic presence with opportunities in biosimilars, complex generics, and international markets. Its strengths in manufacturing, compliance, and product breadth provide a foundation for expansion but require addressing competitive and regulatory challenges.

Key Takeaways

• Pharmascience’s revenue relies predominantly on generic products with constrained international market penetration.
• Its competitive advantage lies in manufacturing capacity and regulatory compliance.
• Strategic focus on biosimilars, complex generics, and international expansion can unlock growth.
• Competition from biosimilars and price pressures risks margin compression.
• Forming strategic alliances will be crucial for entering new markets and accelerating pipeline development.

FAQs

1. What are Pharmascience’s main growth areas?
   Biosimilars and complex generics targeting North American and European markets.

2. How does Pharmascience plan to expand internationally?
   Through regional manufacturing, distribution partnerships, and local licensing agreements.

3. What regulatory hurdles does Pharmascience face?
   Compliance with Health Canada, FDA, and emerging market requirements for product approvals.

4. What is the company's competitive advantage?
   Its manufacturing capacity, broad product portfolio, and regulatory expertise.

5. How might market dynamics impact Pharmascience’s long-term prospects?
   Price pressures and biosimilar competition could compress margins, demanding strategic innovation.

---

References

1. IQVIA. (2022). Canadian Pharmaceutical Market Share Reports.
2. Pharmascience Inc. Annual Report. (2022).
3. U.S. FDA. (2022). Biologics Price Competition and Innovation Act (BPCIA) Regulatory Guidelines.
4. Health Canada. (2022). Drug and Health Product Licensing Advisory.
5. S&P Capital IQ. (2022). Industry and Company Reports.